AI coach takes on diabetes drug: can a smart lifestyle program beat tirzepatide?
NCT ID NCT07697391
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study tests whether an AI-powered intensive lifestyle program can help people with obesity and newly diagnosed type 2 diabetes lose weight and control blood sugar as well as the drug tirzepatide. Adults aged 18 to 65 with a BMI of 28 to 40 and recent diabetes diagnosis are randomly assigned to the AI lifestyle group, tirzepatide injections, or standard lifestyle advice. The main goal is weight loss after one year, with additional checks on blood sugar, body composition, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tirzepatide
- What this could lead to
- If successful, this could show that an AI-guided lifestyle program is as effective as a leading diabetes drug for weight loss and blood sugar control, offering a drug-free option.
- What could go wrong
- This is a single study with 285 participants, and the lifestyle intervention requires high commitment. Results may not apply to everyone, and tirzepatide has known side effects like nausea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230601, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- Kidney clues may predict eye swelling after cataract surgery in diabetes patients
- A daily pill for obesity? zenagamtide faces its biggest test yet.